RT Journal Article
T1 Multiparticulate Systems of Meloxicam for Colonic Administration in Cancer or Autoimmune Diseases
A1 Navarro-Ruíz, Eva
A1 Peña, M Ángeles
A1 Dahma, Zaid
A1 Álvarez Álvarez, Covadonga
A1 Torrado Salmerón, Carlos Félix
A1 Torre Iglesias, Paloma Marina De La
AB The aim of this research is the development of new colonic release systems of meloxicam (MLX) a non-steroidal anti-inflammatory drug (NSAIDs) with pH and time-dependent vehicles for cancer or autoimmune diseases. The colon has a higher pH than the rest of the gastrointestinal tract (GIT) and this can be used as a modified release strategy. Eudragit® polymers are the most widely used synthetic products in the design of colonic release formulations because they might offer mucoadhesiveness and pH-dependent release. Colonic delivery systems produced with pH-dependent and permeable polymers (FS-30D) or with pH-independent and low permeability polymers (NM-30D), must dissolve at a pH range of 6.0–7.0 to delay the release of the drug and prevent degradation in the GIT, before reaching the colon. The conditions prepared to simulate a gastrointestinal transit showed the CNM multiparticulate system, composed of Eudragit® NM and cellulose, as the best release option for MLX with a more sustained release with respect to the other formulations. CNM formulation followed Higuchi and First-order release kinetics, thus MLX release was controlled by a combination of diffusion and polymers swelling/eroding processes.
PB MDPI
SN 1999-4923
YR 2022
FD 2022-07-20
LK https://hdl.handle.net/20.500.14352/92180
UL https://hdl.handle.net/20.500.14352/92180
LA eng
NO NAVARRO-RUÍZ, Eva, et al. Multiparticulate systems of meloxicam for colonic administration in cancer or autoimmune diseases. Pharmaceutics, 2022, vol. 14, no 7, p. 1504.
NO Ministerio de Ciencia e Innovación, España.
NO Universidad Complutense de Madrid
DS Docta Complutense
RD 10 abr 2025